OPTIMIZE was a randomized, open label study, which included 330 patients with chronic kidney disease (CKD) on dialysis with hyperphosphatemia. The study was designed to evaluate different methods of ...

Try Now>> See today’s best-performing stocks on TipRanks Unicycive Therapeutics NewsMORE Related Stocks Indices Commodities Currencies Stocks ...

New Drug Application for hyperphosphatemia in chronic kidney disease patients on dialysis under review by the FDA with a ...

A $160 million South African phosphate mine owned by billionaire Patrice Motsepe’s African Rainbow Capital Investments that’s been beset by environmental disputes for over a decade is facing a ...

Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company or “Unicycive”), today announced that ...

Table of Contents How blood pressure sensing works on a ring? An approach validated by science The dawn of a new era for smart rings Circular is a relatively small player in the smart ring segment ...

SHANGHAI, Feb. 26, 2025 /PRNewswire/ -- Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma; stock code: 600196.SH, 02196.HK) announced that its holding ...

Nat Clin Pract Nephrol. 2006;2(3):136-148. Hypophosphatemia associated with primary hyperparathyroidism is usually of moderate severity; increased urinary phosphate excretion is balanced by ...